Halozyme Therapeutics (NASDAQ:HALO) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.05), Briefing.com reports. The business had revenue of $46.20 million for the quarter, compared to the consensus estimate of $54.96 million. Halozyme Therapeutics had a negative net margin of 23.53% and a negative return on equity of 16.97%. The business’s revenue was up 80.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.19) EPS.
Shares of HALO stock traded up $0.63 on Thursday, hitting $18.30. The stock had a trading volume of 32,464 shares, compared to its average volume of 1,480,984. Halozyme Therapeutics has a twelve month low of $13.24 and a twelve month high of $18.03. The firm has a market cap of $2.43 billion, a P/E ratio of -31.55 and a beta of 1.78. The company has a current ratio of 2.89, a quick ratio of 2.57 and a debt-to-equity ratio of 0.05. The company has a fifty day moving average price of $15.75 and a two-hundred day moving average price of $16.15.
Several brokerages have commented on HALO. BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. ValuEngine lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 21st. BMO Capital Markets boosted their price target on shares of Halozyme Therapeutics from $16.00 to $17.00 and gave the company a “market perform” rating in a report on Wednesday. JPMorgan Chase & Co. boosted their price target on shares of Halozyme Therapeutics from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price target for the company in a report on Thursday, November 7th. Four equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Halozyme Therapeutics has an average rating of “Buy” and an average target price of $20.33.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Recommended Story: What is Net Asset Value (NAV)?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.